Thumbs down for fampridine

European Medicine's agency gives a negative opinion for fampridine:

"The Committee adopted a negative opinion recommending that fampridine, from Biogen-Idec Ltd, should not be granted a marketing authorisation. Fampyra was intended to be used to improve the walking ability of adult patients with multiple sclerosis."

Where to next?

Click here for EMA notification